Standard Follow-up Program (SFP) for Breast Cancer Patients
Launched by UNIVERSITY MEDICAL CENTER GRONINGEN · May 22, 2024
Trial Information
Current as of November 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study, based at the University Medical Center Groningen in the Netherlands, is an observational, long-term follow-up project called the Standard Follow-up Program (SFP MAMMA) for Breast Cancer Patients. It does not test a new drug or device. Instead, researchers are collecting real-world data from women with breast cancer who are receiving radiotherapy, to build a large database that links treatment details with outcomes like tumor control, side effects, and quality of life. The goal is to create models that could help tailor future treatments and decide who might benefit from different radiation approaches, including proton therapy.
Eligibility is for adult women (ages 18 to 99) with breast cancer who will receive radiotherapy. Participation is by invitation, and the study is ongoing with enrollment planned to continue for about 30 years. What participants can expect is regular data collection: blood tests before radiotherapy, and questionnaires about demographics, symptoms, and quality of life at several time points before and after treatment (throughout the following years). Primary outcomes focus on treatment-related side effects (acute during treatment and late afterward), while secondary outcomes include overall survival and control of cancer in the treated area.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients with breast cancer Patients receiving a radiotherapy dose
- Exclusion Criteria:
- • Failure to comply with any of the inclusion criteria
About University Medical Center Groningen
University Medical Center Groningen (UMCG) is a leading academic medical center in the Netherlands, renowned for its commitment to innovative research, high-quality patient care, and extensive education in the medical field. As a prominent sponsor of clinical trials, UMCG leverages its multidisciplinary expertise and state-of-the-art facilities to advance medical knowledge and improve therapeutic outcomes. The center fosters collaboration among researchers, healthcare professionals, and industry partners, aiming to translate scientific discoveries into effective treatments that enhance patient health and well-being. With a focus on ethical standards and regulatory compliance, UMCG is dedicated to conducting clinical trials that contribute to the advancement of medicine and the betterment of society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Groningen, Netherlands
Patients applied
Trial Officials
Anne Crijns, MD, PhD
Principal Investigator
UMCG
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported